The DOI matches its Crossref record; 64 of the 67 references it cites were found in a registry or an index.
Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane Therapy
Open accessAbstract
Adrenocortical carcinoma is a rare tumor, and only limited information is available about its natural history and the effects of therapy. We studied 105 patients (75 female and 30 male; mean age, 46 years) with adrenocortical carcinoma who were referred to us between 1963 and 1987. The average duration of symptoms before diagnosis was 8.7 months. At the time of diagnosis, 68 percent of the patients had endocrine symptoms, and 30 percent had distant metastases. Hormonal studies showed that 79 percent of the tumors were functional. Eighty patients underwent surgery, and 59 also received the adrenal cytotoxic agent mitotane. The median disease-free interval after surgery was 12.1 months (range, 1 to 175). Tumor dissemination occurred in 82 percent of the patients, most commonly to the lung, liver, and adjacent organs. The median survival time was 14.5 months (range, less than 1 to 175), and the five-year survival was 22 percent. Age over 40 years and the presence of metastases at the time of diagnosis were the only factors recognized as indicating a poor prognosis. Mitotane controlled hormonal secretion in 75 percent of the patients. Eight mitotane-treated patients had partial tumor regression, but the drug did not have a significant effect on survival. We conclude that adrenocortical carcinoma carries a poor prognosis. Mitotane therapy may offer transient benefits, particularly in controlling endocrine symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in accordance with a median age of 46 years in a large single center series in France (10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“In the adult as well as in the pediatric population, there is a predilection for the female gender (the ratio of female to male ranges from 1.5–2.5:1) (10, 17).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“A role of estrogens has also been suggested by the observation of a probable relative increase of diagnosis of ACC during pregnancy (10, 19).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“For 40% to 60% of patients, the major presenting complaints are symptoms and signs of hormone excess (3, 9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Another third present with nonspecific symptoms due to local tumor growth, such as abdominal or flank pain, abdominal fullness, or early satiety (9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Patients with ACC only rarely present with classical tumor symptoms, such as cachexia or night sweats (3, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Biochemically or clinically apparent adrenocortical hormone production is evident in up to 45% to 70% (9, 10, 85).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Hypercortisolism is the most common presentation of patients presenting with hormone excess (50%–80% of hormone-secreting ACCs), causing classic symptoms including plethora, diabetes mellitus, muscle weakness/atrophy, and osteoporosis.”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Murphy, B. E. P. (1967) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-27-7-973 · Cited by 1,998
Incidence of malignant tumors in U.S. children
Young, J. L., & Miller, R. W. (1975) · The Journal of Pediatrics · doi:10.1016/s0022-3476(75)80484-7 · Cited by 842
On Distribution-Free Tests for Equality of Survival Distributions
Tarone, R. E., & Ware, J. S. (1977) · Biometrika · doi:10.1093/biomet/64.1.156 · Cited by 733
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Rubinstein, L. J., Herman, M. M., Long, T. F., & Wilbur, J. R. (1975) · Cancer · doi:10.1002/1097-0142(197502)35:2 · Cited by 383
Results of Treatment in 108 Patients with Cushing's Syndrome
Orth, D. N., & Liddle, G. W. (1971) · New England Journal of Medicine · doi:10.1056/nejm197107292850501 · Cited by 327
Research works printed but not linked: 21
- Plager, 1984, Int Adv Surg Oncol, 7, 329
- Macfarlane, 1958, Ann R Coll Surg Engl, 23, 155
- Heinbecker, 1957, Surg Gynecol Obstet, 105, 21
- Brennan, 1987, CA, 37, 348
- Bradley, 1975, Surg Gynecol Obstet, 141, 507
- Greenberg, 1978, Am Surg, 44, 81
- Ostuni, 1975, Arch Intern Med, 135, 1257, 10.1001/archinte.1975.00330090129015 · DOI
- Haq, 1980, Cancer Treat Rep, 64, 909
- Bricaire, 1977, Nouv Presse Med, 6, 3650
- Rappaport, 1978, Arch Fr Pediatr, 35, 551
- Levine, 1978, Am J Dis Child, 132, 238
- Lejonc, 1978, Nouv Presse Med, 7, 3147
- Pugeat, 1980, Ann Endocrinol, 41, 107
- Cathelineau, 1980, Ann Endocrinol, 41, 65
- Cassan, 1978, Nouv Presse Med, 7, 2153
- Benaily, 1975, Arch Fr Pediatr, 32, 441
- Cariou, 1982, Nouv Presse Med, 11, 2821
- Charbonnel, 1980, Nouv Presse Med, 9, 239
- Jarabak, 1981, JAMA, 246, 1706, 10.1001/jama.1981.03320150054033 · DOI
- Levy, 1985, Ann Pediatr (Paris), 32, 541
- du Rostu, 1987, Presse Med, 16, 951
Cited by
Sorted by citations
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 907
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Metadata
- Authors
- Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., Bonnin, A., & Bricaire, H.
- Affiliations
- Hôpital Cochin (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-04-26
- Volume
- 322
- Issue
- 17
- Pages
- 1195-1201
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336089418
- Cited by
- 717
- References
- 67
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 15 · 2023: 26 · 2022: 22 · 2021: 31 · 2020: 20 · 2019: 17 · 2018: 23 · 2017: 16 · 2016: 19 · 2015: 27 · 2014: 25 · 2013: 19 · 2012: 31
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, mitotane, prognostic factors, adrenal surgery, metastasis, survival, endocrine symptoms, tumor regression, adrenocortical function, age over 40
- MeSH terms
- Adrenal Cortex Hormones, Adrenal Cortex Neoplasms, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mitotane, Neoplasm Metastasis, Prognosis, Retrospective Studies, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
